Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 360

1.

Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?

Feldmann M, Maini RN.

J Immunol. 2010 Jul 15;185(2):791-4. doi: 10.4049/jimmunol.1090051.

2.

Anti-TNF therapy from the bench to the clinic: a paradigm of translational research.

Maini RN.

Clin Med. 2010 Apr;10(2):161-2. No abstract available.

PMID:
20437991
3.

Introducing Arthritis Research & Therapy's 10th anniversary issue, 'The Scientific Basis of Rheumatology: A Decade of Progress'.

Hrynaszkiewicz I, Lipsky PE, Maini RN.

Arthritis Res Ther. 2008;10(5):119. doi: 10.1186/ar2522. Epub 2008 Oct 10. No abstract available.

4.

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.

Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair EW; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.

Ann Rheum Dis. 2009 Jun;68(6):823-7. doi: 10.1136/ard.2008.090019. Epub 2008 Jul 1. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
18593759
5.

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katasikis P, Brennan FM, Bijl H, Ghrayeb J, Woody JN.

Arthritis Rheum. 2008 Feb;58(2 Suppl):S92-S101. doi: 10.1002/art.23362.

6.

The pitfalls in the development of biologic therapy.

Maini RN, Feldmann M.

Nat Clin Pract Rheumatol. 2007 Jan;3(1):1. No abstract available.

PMID:
17202998
7.

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T; CHARISMA Study Group.

Arthritis Rheum. 2006 Sep;54(9):2817-29. Erratum in: Arthritis Rheum. 2008 Mar;58(3):887.

8.

Interleukin-6: a new therapeutic target.

Smolen JS, Maini RN.

Arthritis Res Ther. 2006;8 Suppl 2:S5. Epub 2006 Jul 28. Review. Erratum in: Arthritis Res Ther. 2006;8(6):407.

9.

Infliximab treatment maintains employability in patients with early rheumatoid arthritis.

Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, Kalden JR, Schiff M, Bala M, Baker D, Han J, Maini RN, St Clair EW.

Arthritis Rheum. 2006 Mar;54(3):716-22.

10.

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.

Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.

Arthritis Rheum. 2006 Mar;54(3):702-10.

11.
12.

Anti-TNF therapy: where have we got to in 2005?

Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN.

J Autoimmun. 2005;25 Suppl:26-8. Epub 2005 Nov 2. Review.

PMID:
16260118
15.

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group.

Arthritis Rheum. 2004 Nov;50(11):3432-43.

16.

Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis.

Breedveld FC, Han C, Bala M, van der Heijde D, Baker D, Kavanaugh AF, Maini RN, Lipsky PE.

Ann Rheum Dis. 2005 Jan;64(1):52-5. Epub 2004 Jul 29.

17.

Current and new antitumor necrosis factor agents in perspective.

Maini RN.

Arthritis Res Ther. 2004;6 Suppl 2:S1-2. Epub 2004 Jun 21. Review. No abstract available.

18.

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.

Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN.

Best Pract Res Clin Rheumatol. 2004 Feb;18(1):59-80. Review.

PMID:
15123038
19.

Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.

Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, Wagner CL, McClinton C, Maini RN.

Arthritis Rheum. 2004 Apr;50(4):1107-16.

20.

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Arthritis Rheum. 2004 Apr;50(4):1051-65.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk